加载中
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
前收盘价
US$1.85
−US$0.16 · -7.96%
盘中时间采用ET。市场数据可能有所延迟。
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
日内区间
当前US$1.85
52周区间
当前US$1.85
盘中时间采用ET。市场数据可能有所延迟。
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
日内区间
当前US$1.85
52周区间
当前US$1.85
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1385.8万 USD | 1614.6万 USD | — | — | — |
| 销货成本 | 238.8万 USD | 47.5万 USD | — | — | — |
| 毛利 | 1147万 USD | 1567.1万 USD | — | — | — |
| 研究与开发 | 7369.6万 USD | 5874.7万 USD | 4958.6万 USD | 8612.9万 USD | 5105.4万 USD |
| 销售、一般及管理费用 | 2219.4万 USD | 2542万 USD | 3261万 USD | 3735.2万 USD | 1866.3万 USD |
| 营业费用 | 9589万 USD | 1.05亿 USD | 8219.6万 USD | 1.23亿 USD | 6971.7万 USD |
| 利息收入 | 361万 USD | 703.9万 USD | 663万 USD | 276.4万 USD | 2.3万 USD |
| 折旧和摊销 | 451.1万 USD | 298.2万 USD | 192.7万 USD | 70.9万 USD | 64.7万 USD |
| 营业利润 | −8442万 USD | −8946万 USD | −8219.6万 USD | −1.23亿 USD | −6971.7万 USD |
| 净利润 | −7962.1万 USD | −7733.1万 USD | −7379万 USD | −1.21亿 USD | −7597.5万 USD |
公司数据更新于 2026年10月14日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI522.3万0.00%2.3万亿 USD0.03%US$381.32—
Vanguard Extended Market ETFVXF194.46万0.00%954亿 USD0.05%US$232.54—
iShares Biotechnology ETFIBB106.91万0.01%107.38亿 USD0.44%US$200.02—
iShares Micro-Cap ETFIWC30.91万0.02%13.07亿 USD0.60%US$179.6—
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM19万0.16%1.16亿 USD0.73%US$15.6501—
Invesco Nasdaq Biotechnology ETFIBBQ1.26万0.01%1.11亿 USD0.19%US$33.4334—
ProShares Ultra Nasdaq BiotechnologyBIB6440.040.01%——US$103.59—Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
